Ask AI
ProCE Banner Activity

Perspectiva europea sobre los enfoques actuales para optimizar la atención de los pacientes con linfoma de células del manto

PDF

En este artículo, un experto aborda el papel cada vez más importante de los inhibidores de BTK y los regímenes sin quimioterapia en el tratamiento de pacientes con LCM, así como la importancia de manejar de forma proactiva los efectos adversos relacionados con el tratamiento para prolongar la duración de este y mejorar los resultados clínicos y la calidad de vida.

Released: February 24, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by an educational grant from AstraZeneca.

AstraZeneca

Target Audience

This activity is intended for global hematology/oncology physician specialists and other healthcare professionals providing care for patients with mantle cell lymphoma.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Plan BTK inhibitor-based combination strategies for patients with treatment-naïve MCL, considering new indications, expert recommendations, and available efficacy and safety evidence

  • Select chemotherapy-free treatment strategies for appropriate patients with MCL

  • Manage treatment-related adverse events associated with targeted therapies alone or in combination to extend duration on treatment and improve clinical outcomes